View in EDS

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.

Saved in:
Bibliographic Details
Title: GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.
Authors: Ho VT; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Kim HT; Department of Data Science, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA., Brock J; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Galinsky I; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Daley H; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Reynolds C; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Weber A; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Pozdnyakova O; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Severgnini M; Center for Immuno-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Nikiforow S; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Cutler C; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Koreth J; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Alyea EP; Department of Hematology/Oncology, Duke Cancer Institute, Durham, NC., Antin JH; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Gooptu M; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Romee R; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Shapiro R; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Chen YB; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA., Rosenblatt J; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and., Avigan D; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and., Hodi FS; Center for Immuno-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Dranoff G; Novartis Institutes for BioMedical Research, Boston, MA., Wu CJ; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Ritz J; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Soiffer RJ; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Source: Blood advances [Blood Adv] 2022 Apr 12; Vol. 6 (7), pp. 2183-2194.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34807983
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ho+VT%22">Ho VT</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Kim+HT%22">Kim HT</searchLink>; Department of Data Science, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Brock+J%22">Brock J</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Galinsky+I%22">Galinsky I</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Daley+H%22">Daley H</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Reynolds+C%22">Reynolds C</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Weber+A%22">Weber A</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Pozdnyakova+O%22">Pozdnyakova O</searchLink>; Department of Pathology, Brigham and Women's Hospital, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Severgnini+M%22">Severgnini M</searchLink>; Center for Immuno-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Nikiforow+S%22">Nikiforow S</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Cutler+C%22">Cutler C</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Koreth+J%22">Koreth J</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Alyea+EP%22">Alyea EP</searchLink>; Department of Hematology/Oncology, Duke Cancer Institute, Durham, NC.<br /><searchLink fieldCode="AU" term="%22Antin+JH%22">Antin JH</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Gooptu+M%22">Gooptu M</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Romee+R%22">Romee R</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Shapiro+R%22">Shapiro R</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Chen+YB%22">Chen YB</searchLink>; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Rosenblatt+J%22">Rosenblatt J</searchLink>; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and.<br /><searchLink fieldCode="AU" term="%22Avigan+D%22">Avigan D</searchLink>; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and.<br /><searchLink fieldCode="AU" term="%22Hodi+FS%22">Hodi FS</searchLink>; Center for Immuno-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Dranoff+G%22">Dranoff G</searchLink>; Novartis Institutes for BioMedical Research, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wu+CJ%22">Wu CJ</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Ritz+J%22">Ritz J</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Soiffer+RJ%22">Soiffer RJ</searchLink>; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2022 Apr 12; Vol. 6 (7), pp. 2183-2194.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34807983
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2021006255
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2183
    Titles:
      – TitleFull: GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ho VT
      – PersonEntity:
          Name:
            NameFull: Kim HT
      – PersonEntity:
          Name:
            NameFull: Brock J
      – PersonEntity:
          Name:
            NameFull: Galinsky I
      – PersonEntity:
          Name:
            NameFull: Daley H
      – PersonEntity:
          Name:
            NameFull: Reynolds C
      – PersonEntity:
          Name:
            NameFull: Weber A
      – PersonEntity:
          Name:
            NameFull: Pozdnyakova O
      – PersonEntity:
          Name:
            NameFull: Severgnini M
      – PersonEntity:
          Name:
            NameFull: Nikiforow S
      – PersonEntity:
          Name:
            NameFull: Cutler C
      – PersonEntity:
          Name:
            NameFull: Koreth J
      – PersonEntity:
          Name:
            NameFull: Alyea EP
      – PersonEntity:
          Name:
            NameFull: Antin JH
      – PersonEntity:
          Name:
            NameFull: Gooptu M
      – PersonEntity:
          Name:
            NameFull: Romee R
      – PersonEntity:
          Name:
            NameFull: Shapiro R
      – PersonEntity:
          Name:
            NameFull: Chen YB
      – PersonEntity:
          Name:
            NameFull: Rosenblatt J
      – PersonEntity:
          Name:
            NameFull: Avigan D
      – PersonEntity:
          Name:
            NameFull: Hodi FS
      – PersonEntity:
          Name:
            NameFull: Dranoff G
      – PersonEntity:
          Name:
            NameFull: Wu CJ
      – PersonEntity:
          Name:
            NameFull: Ritz J
      – PersonEntity:
          Name:
            NameFull: Soiffer RJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 04
              Text: 2022 Apr 12
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1